Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. (June 2015)

• Record Type: Journal Article
• Authors: Zanardi, Elisa; Verzoni, Elena; Grassi, Paolo; Necchi, Andrea; Giannatempo, Patrizia; Raggi, Daniele; De Braud, Filippo; Procopio, Giuseppe
• Is Part Of: Therapeutic advances in urology. Volume 7:Number 3(2015:Jun.)
• Page Start: 152
• Page End: 161
• Publication Date: 2015-06
• Subjects: mTOR inhibitors -- renal cell carcinoma -- targeted therapies -- temsirolimus; Urology -- Periodicals; Urologic Diseases -- therapy -- Periodicals; Genital Diseases, Male -- therapy -- Periodicals; Urologie -- Périodiques; 616.6005
• DOI: 10.1177/1756287215574457
• Languages: English
• ISSNs: 1756-2872

Abstract

Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients classified as poor risk. The benefits of temsirolimus are not limited to an increased survival but are also related to a better quality of life, which is certainly one of the most important aspects in the clinical management of these frail patients. Temsirolimus is a well-tolerated treatment, and the most frequent adverse events are manageable with supportive care. To this end, the identification of predictive factors of response to temsirolimus could help us to better select patients and obtain a more tailored clinical management of mRCC.